NewAmsterdam Pharma Company N.V. (NAMS)
InfravaloradaFundamental
28
Precio
$24.61
Capitalización Bursátil
$2.91B
Parte 1 · Cuánto vale la empresa
Resumen
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
Merck's oral PCSK9 inhibitor enlicitide (Lipfendra) targets exactly the same patients obicetrapib is aimed at — people whose LDL cholesterol stays high on statins — and, like obicetrapib, it is a daily pill rather than an injection.
Amgen's Repatha (evolocumab) is the leading add-on therapy for lowering LDL cholesterol on top of statins, the same commercial slot obicetrapib is being positioned for.
Regeneron, with Sanofi, sells Praluent (alirocumab), one of the two injectable PCSK9 inhibitors NewAmsterdam's own filings name as the benchmark obicetrapib is measured against.
AstraZeneca is developing AZD0780, an oral LDL-lowering pill cited in NewAmsterdam's risk factors as a rival for the same prescriptions obicetrapib is seeking.
Esperion sells Nexletol and Nexlizet, the oral non-statin pills prescribed today to the statin-treated patients NewAmsterdam wants to reach, and the 10-K names them among the therapies obicetrapib would have to displace.
Novartis markets Leqvio (inclisiran), a twice-yearly injection sold to cardiologists and lipid clinics for the same high-risk cardiovascular patients obicetrapib would treat.
Balance y Liquidez
Ingresos
$7M
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-260M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$-148M
Patrimonio Neto Total
$683M
Pasivo Total
$86M
Ratio de Liquidez
9.03
Cobertura de Intereses
-
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$33.85
Precio Actual
$24.61
Margen de Seguridad
+27.3%
Rango de Valor Justo
$22.00 - $45.70
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
-29.8%
Ratio P/B
4.60
P/FCF
-
Margen Bruto
-
ROIC
-30.6%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
-30.6%
WACC
8.0%
ROIC − WACC
-38.6 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (6)
- EPS shows upward trend
- Price CAGR 18.40%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 91% Buy
Fallido (11)
- ROIC -30.6%
- P/B Ratio 4.60
- Operating Margin -3432.2%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -38.3%
- Earnings Surprise avg -23.2%
- Share Dilution 25.6%
- Net Margin Trend -3644.2% vs -258.9%
- Piotroski F-Score 3/9
No disponible (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Participaciones institucionales
No hay declaraciones institucionales para esta empresa.
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President & Executive Director | 69 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 71 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 51 |
| Mr. Robert W. Gunning C.P.A., CGMA | Principal Accounting Officer, VP & Controller | 54 |
| Mr. Matthew Philippe | Executive VP & Head of Investor Relations | - |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary | 49 |
| Mr. Chris Deluzio | Executive Vice President of Sales Enterprise Operations | - |
| Ms. Maryellen McQuade | Chief People Officer | - |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer | 38 |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer | 58 |
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-18
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-08-05
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-09-29
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for NAMS, sourced from Markets Gazette.